ORASURE TECHNOLOGIES INCOSUREarnings & Financial Report
OraSure Technologies, Inc. is a Bethlehem, Pennsylvania–based company in the medical device industry. Their products include diagnostic testing kits. The company had recently developed OraQuick testing kit, the first over-the-counter home HIV test.
OSUR Q4 FY2025 Key Financial Metrics
Revenue
$26.8M
Gross Profit
$11.0M
Operating Profit
$-20.1M
Net Profit
$-19.3M
Gross Margin
41.0%
Operating Margin
-75.1%
Net Margin
-72.1%
YoY Growth
-28.5%
EPS
$-0.28
ORASURE TECHNOLOGIES INC Q4 FY2025 Financial Summary
ORASURE TECHNOLOGIES INC reported revenue of $26.8M (down 28.5% YoY) for Q4 FY2025, with a net profit of $-19.3M (down 78.7% YoY) (-72.1% margin). Cost of goods sold was $15.8M, operating expenses totaled $31.1M.
Key Financial Metrics
| Total Revenue | $26.8M |
|---|---|
| Net Profit | $-19.3M |
| Gross Margin | 41.0% |
| Operating Margin | -75.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
ORASURE TECHNOLOGIES INC Q4 FY2025 revenue of $26.8M breaks down across 2 segments, led by Product And Services at $24.9M (92.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product And Services | $24.9M | 92.9% |
| Other | $1.9M | 7.1% |
ORASURE TECHNOLOGIES INC Revenue by Segment — Quarterly Trend
ORASURE TECHNOLOGIES INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Product And Services and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Product And Services | $24.9M | $25.3M | $29.8M | — |
| Other | $1.9M | — | — | — |
ORASURE TECHNOLOGIES INC Annual Revenue by Year
ORASURE TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $115.0M).
ORASURE TECHNOLOGIES INC Quarterly Revenue & Net Profit History
ORASURE TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.8M | -28.5% | $-19.3M | -72.1% |
| Q3 FY2025 | $27.1M | -32.1% | $-13.7M | -50.6% |
| Q2 FY2025 | $31.2M | -42.5% | $-19.7M | -63.0% |
| Q1 FY2025 | $29.9M | -44.7% | $-16.0M | -53.6% |
| Q4 FY2024 | $37.4M | -50.7% | $-10.8M | -28.8% |
| Q3 FY2024 | $39.9M | -55.2% | $-4.5M | -11.3% |
| Q2 FY2024 | $54.3M | -36.4% | $-615.0K | -1.1% |
| Q1 FY2024 | $54.1M | -65.1% | $-3.6M | -6.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.1M | $54.3M | $39.9M | $37.4M | $29.9M | $31.2M | $27.1M | $26.8M |
| YoY Growth | -65.1% | -36.4% | -55.2% | -50.7% | -44.7% | -42.5% | -32.1% | -28.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $467.6M | $466.3M | $464.1M | $479.7M | $457.6M | $445.0M | $423.1M | $403.2M |
| Liabilities | $41.3M | $40.5M | $38.5M | $69.3M | $61.3M | $64.3M | $61.1M | $62.3M |
| Equity | $426.3M | $425.8M | $425.6M | $410.3M | $396.3M | $380.7M | $362.0M | $340.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $6.7M | $7.8M | $12.7M | $109000 | $-19.7M | $-10.2M | $-10.1M | $-9.0M |